Methodological Insights for Randomized Clinical Trials of Retinitis Pigmentosa: Lessons Learned From a Trial of Valproic Acid
- PMID: 29879289
- PMCID: PMC11553231
- DOI: 10.1001/jamaophthalmol.2018.1167
Methodological Insights for Randomized Clinical Trials of Retinitis Pigmentosa: Lessons Learned From a Trial of Valproic Acid
Conflict of interest statement
Comment on
-
Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial.JAMA Ophthalmol. 2018 Aug 1;136(8):849-856. doi: 10.1001/jamaophthalmol.2018.1171. JAMA Ophthalmol. 2018. PMID: 29879277 Free PMC article. Clinical Trial.
References
-
- Birch DG, Bernstein PS, Iannacone A, et al. Effect of oral valproic acid vs placebo for vision loss in patients with autosomal dominant retinitis pigmentosa: a randomized phase 2 multicenter placebo-controlled clinical trial [published online June 7, 2018]. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2018.1171 - DOI - PMC - PubMed
-
- Retinitis Pigmentosa. Foundation for Fighting Blindess. http://www.blindness.org/retinitis-pigmentosa. Accessed March 30, 2018.
-
- Numbers of people with macular degeneration and other retinal diseases. Prevent Blindness. http://lowvision.preventblindness.org/eye-conditions/numbers-of-people-w.... Accessed March 30, 2018.
-
- Strauss RW, Ho A, Muñoz B, et al.; Progression of Stargardt Disease Study Group. The natural history of the progression of atrophy secondary to Stargardt Disease (ProgStar) studies. Ophthalmology. 2016;123(4):817–828. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
